PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Prednisone and Abiraterone Interaction

Drug interaction information between Prednisone and Abiraterone.

Prednisone and Abiraterone have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Prednisone and Abiraterone. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.

Drug A

Prednisone

Corticosteroid

Drug B

Abiraterone

CYP17 Inhibitor

How They Interact

Taking these two drugs together can change how your liver processes other common medications, potentially causing those other drugs to build up in your system.

What To Do

Your doctor should review all your other medicines to ensure their levels do not become too high while you are taking this combination.

FDA Label Information

In a CYP2D6 drug-drug interaction trial, the C max and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily.

Frequently Asked Questions

Can I take Prednisone and Abiraterone together?

This is a minor interaction. Your doctor should review all your other medicines to ensure their levels do not become too high while you are taking this combination.

How serious is the interaction between Prednisone and Abiraterone?

This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.

Why do Prednisone and Abiraterone interact?

Taking these two drugs together can change how your liver processes other common medications, potentially causing those other drugs to build up in your system.

Understanding the Prednisone and Abiraterone Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Prednisone belongs to the Corticosteroid class and Abiraterone belongs to the CYP17 Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking these two drugs together can change how your liver processes other common medications, potentially causing those other drugs to build up in your system. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Prednisone has 9 total documented interactions on file in this dataset, and Abiraterone has 7. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should review all your other medicines to ensure their levels do not become too high while you are taking this combination. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Prednisone or Abiraterone based on a web page, speak with your prescriber or pharmacist before making any change.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.